Welcome to the 2008 AUA Meeting Preview

Article

Welcome to the AUA annual meeting preview, brought to you by the editorial staff of Urology Times.

Welcome to the AUA annual meeting preview, brought to you by the editorial staff of Urology Times.

This newsletter offers a guide to Orlando attractions, and previews the Exhibit Hall.

Coming Sunday . . .Look for our Daily Meeting Report e-newsletter, delivered to your in-box, May 18-22.

Please make sure you visit the Urology Times exhibit (Booth #1245) where you will be able to:

  • Renew your subscriptions to our journals.
  • Sign up for our eDaily Meeting Report e-newsletter and Daily Podcast.

We look forward to seeing you in Orlando!

Enjoy the meeting.

Recent Videos
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Emily Sopko, CNP, answers a question during a Zoom video interview
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom virtual interview
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Long hospital bright corridor with rooms and seats 3D rendering | Image Credit: © sdecoret - stock.adobe.com
Related Content
Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke
September 6th 2024
Article

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
July 24th 2024
Podcast

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Darolutamide associated with more favorable tolerability vs other ARIs in nmCRPC

Darolutamide associated with more favorable tolerability vs other ARIs in nmCRPC

Hannah Clarke
September 5th 2024
Article

“Our study reveals potential differences in tolerance and effectiveness of AR inhibitors in practice, which can help clinicians and patients with treatment decisions," says Daniel J. George, MD.

Health policy in urology: 2024 AUA Advocacy Summit recap

Health policy in urology: 2024 AUA Advocacy Summit recap

Urology Times staff
March 21st 2024
Podcast

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

Study reveals disparities in immunotherapy use for patients with kidney, bladder cancer

Study reveals disparities in immunotherapy use for patients with kidney, bladder cancer

Hannah Clarke
September 4th 2024
Article

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke
September 4th 2024
Article

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

© 2024 MJH Life Sciences

All rights reserved.